ArticleToxics2024
Temporal Trend of Serum Perfluorooctanoic Acid and Perfluorooctane Sulfonic Acid among U.S. Adults with or without Comorbidities in NHANES 1999-2018.
Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- GenX exposure induces neurodevelopmental impairment and synaptic toxicity in hESC-derived cerebral organoids.Materials today. Bio · 2026Article
- Time-Dependent Effects of PFAS and Their Mixtures on Ovarian Epithelial Cell Proliferation and Chemotherapeutic Response.International journal of molecular sciences · 2026Article
- Risk Assessment of PFAS-Induced Male Reproductive Toxicity: A Comprehensive Evaluation Using the TRAEC Strategy.Environment & health (Washington, D.C.) · 2026Article
- Chronic PFOA and PFOS exposure triggers cellular oxidative stress and alters lipid levels as revealed through multi-omics analysis.Environmental science. Advances · 2026Article
- Long-Term Per- and Polyfluoroalkyl Substances Exposure and Kidney Function in Taiwanese Adolescents and Young Adults: A 10-Year Prospective Cohort Study.Journal of xenobiotics · 2026Article
- The moderating role of vitamin E in the association between PFAS exposures and diabetes risk: Evidence from the NHANES 2017-2018.Metabolism open · 2025Article
- Per- and Polyfluoroalkyl Substances (PFAS): History, Current Concerns, and Future Outlook.Molecules (Basel, Switzerland) · 2025Review
- Prenatal Per- and Polyfluoroalkyl Substances (PFAS) Exposures, Newborn Mitochondrial DNA Copy Number, and the Modifying Role of the Maternal Folate Level.Environmental science & technology · 2025Article
- Associations of early life per- and polyfluoroalkyl substances (PFAS) exposure with body mass index and risk of overweight or obesity at age 2-18 years: Mixture analysis in the prospective Boston Birth Cohort.Environment international · 2025Article
- Cord plasma metabolomic signatures of prenatal per- and polyfluoroalkyl substance (PFAS) exposures in the Boston Birth Cohort.Environment international · 2024Article
- Association between family economic situation and serum PFAS concentration in American adults with hypertension and hyperlipemia.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are associated with adverse health effects. This study examined the trend of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) levels in individuals with and without pre-existing comorbidities. We analyzed the characteristics of 13,887 participants across nine U.S. NHANES cycles (1999-2000 to 2017-2018) and calculated the geometric mean (GM) of PFOA and PFOS levels, standardized by sex and age. A joinpoint regression model was used to analyze the temporal trends of serum PFOA and PFOS levels. We observed declining PFOA and PFOS serum levels among adults in NHANES from 1999-2000 to 2017-2018. Serum PFOA and PFOS concentrations were higher in men, smokers, and individuals with pre-existing CKD, hyperlipidemia, CVD, and cancer. We observed faster decline rates in PFOA levels among individuals with diabetes and CKD and faster decline rates in PFOS levels among individuals with diabetes and those without CKD. This study provided evidence of varying levels and changing trends of PFOA and PFOS between groups with and without established chronic disease, highlighting the role of environmental chemicals in the onset and development of chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.